Literature DB >> 33006916

Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.

Wan-Chun Chang1,2, Reo Tanoshima1,2, Colin J D Ross2,3, Bruce C Carleton1,2,4.   

Abstract

The clinical implementation of pharmacogenetic biomarkers continues to grow as new genetic variants associated with drug outcomes are discovered and validated. The number of drug labels that contain pharmacogenetic information also continues to expand. Published, peer-reviewed clinical practice guidelines have also been developed to support the implementation of pharmacogenetic tests. Incorporating pharmacogenetic information into health care benefits patients as well as clinicians by improving drug safety and reducing empiricism in drug selection. Barriers to the implementation of pharmacogenetic testing remain. This review explores current pharmacogenetic implementation initiatives with a focus on the challenges of pharmacogenetic implementation and potential opportunities to overcome these challenges.

Entities:  

Keywords:  adverse drug reaction; clinical implementation; drug effectiveness; drug safety; pharmacogenetics; pharmacogenomics

Year:  2020        PMID: 33006916     DOI: 10.1146/annurev-pharmtox-030920-025745

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  5 in total

1.  A blockchain-based framework to support pharmacogenetic data sharing.

Authors:  F Albalwy; J H McDermott; W G Newman; A Brass; A Davies
Journal:  Pharmacogenomics J       Date:  2022-07-22       Impact factor: 3.245

2.  Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid Populations.

Authors:  Camila Farinango; Jennifer Gallardo-Cóndor; Byron Freire-Paspuel; Rodrigo Flores-Espinoza; Gabriela Jaramillo-Koupermann; Andrés López-Cortés; Germán Burgos; Eduardo Tejera; Alejandro Cabrera-Andrade
Journal:  J Pers Med       Date:  2022-06-10

3.  Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.

Authors:  Ursina B M Begré; Markus Jörger; Stefan Aebi; Ursula Amstutz; Carlo R Largiadèr
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

4.  Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents.

Authors:  Rosario Iemmolo; Valentina La Cognata; Giovanna Morello; Maria Guarnaccia; Mariamena Arbitrio; Enrico Alessi; Sebastiano Cavallaro
Journal:  Biosensors (Basel)       Date:  2020-12-09

5.  Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program.

Authors:  Joseph P Jarvis; Arul Prakasam Peter; Murray Keogh; Vince Baldasare; Gina M Beanland; Zachary T Wilkerson; Steven Kradel; Jeffrey A Shaman
Journal:  J Pers Med       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.